These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele. Bader AG; Hartl M; Bister K Virology; 2000 Apr; 270(1):98-110. PubMed ID: 10772983 [TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle arises as a late event during development of wound sarcomas in v-jun transgenic mice. Schuh AC; Keating SJ; Yeung MC; Breitman ML Oncogene; 1992 Apr; 7(4):667-76. PubMed ID: 1314368 [TBL] [Abstract][Full Text] [Related]
6. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Bader AG; Schneider ML; Bister K; Hartl M Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724 [TBL] [Abstract][Full Text] [Related]
7. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts. Basso J; Briggs J; Findlay C; Bos T Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905 [TBL] [Abstract][Full Text] [Related]
8. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737 [TBL] [Abstract][Full Text] [Related]
10. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Wang ZQ; Liang J; Schellander K; Wagner EF; Grigoriadis AE Cancer Res; 1995 Dec; 55(24):6244-51. PubMed ID: 8521421 [TBL] [Abstract][Full Text] [Related]
12. v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Iacovoni JS; Cohen SB; Berg T; Vogt PK Oncogene; 2004 Jul; 23(33):5703-6. PubMed ID: 15133497 [TBL] [Abstract][Full Text] [Related]
13. Activation and inhibition of the AP-1 complex in human breast cancer cells. Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534 [TBL] [Abstract][Full Text] [Related]
14. Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis. Schuh AC; Theodorescu D; Shalaby F; Breitman ML Cell Growth Differ; 1993 Mar; 4(3):177-84. PubMed ID: 8466856 [TBL] [Abstract][Full Text] [Related]
15. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences. Hadman M; Loo M; Bos TJ Oncogene; 1993 Jul; 8(7):1895-903. PubMed ID: 8510933 [TBL] [Abstract][Full Text] [Related]
16. Two distinct target cells for v-jun mediated wound tumorigenesis. Shalaby F; Schuh AC; Breitman ML Oncogene; 1994 Sep; 9(9):2579-88. PubMed ID: 8058321 [TBL] [Abstract][Full Text] [Related]
18. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors. Vial E; Perez S; Castellazzi M Oncogene; 2000 Oct; 19(43):5020-9. PubMed ID: 11042689 [TBL] [Abstract][Full Text] [Related]
19. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Echlin DR; Tae HJ; Mitin N; Taparowsky EJ Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209 [TBL] [Abstract][Full Text] [Related]
20. Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells. Li J; Johnson TA; Hanson LA; Beer DG Mol Carcinog; 1996 Aug; 16(4):213-20. PubMed ID: 8784464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]